No Cover Image

Journal article 116 views

Current management of chronic kidney disease in type‐2 diabetes—A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney association ( ABCD ‐ UKKA ) guidelines

Indranil Dasgupta Orcid Logo, Sagen Zac‐Varghese, Khuram Chaudhry, Kieran McCafferty, Peter Winocour Orcid Logo, Tahseen A. Chowdhury Orcid Logo, Srikanth Bellary, Gabrielle Goldet, Mona Wahba, Parijat De, Andrew H. Frankel, Rosa M. Montero, Eirini Lioudaki, Debasish Banerjee Orcid Logo, Ritwika Mallik, Adnan Sharif, Naresh Kanumilli, Nicola Milne, Dipesh C. Patel, Ketan Dhatariya Orcid Logo, Steve Bain Orcid Logo, Janaka Karalliedde Orcid Logo

Diabetic Medicine

Swansea University Author: Steve Bain Orcid Logo

Full text not available from this repository: check for access using links below.

Check full text

DOI (Published version): 10.1111/dme.15450

Abstract

A growing and significant number of people with diabetes develop chronic kidney disease (CKD). Diabetes‐related CKD is a leading cause of end‐stage kidney disease (ESKD) and people with diabetes and CKD have high morbidity and mortality, predominantly related to cardiovascular disease (CVD). Despite...

Full description

Published in: Diabetic Medicine
ISSN: 0742-3071 1464-5491
Published: Wiley 2024
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa68024
first_indexed 2024-10-18T10:28:49Z
last_indexed 2024-11-28T19:46:45Z
id cronfa68024
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2024-11-28T15:14:33.4235232</datestamp><bib-version>v2</bib-version><id>68024</id><entry>2024-10-18</entry><title>Current management of chronic kidney disease in type&#x2010;2 diabetes&#x2014;A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney association ( ABCD &#x2010; UKKA ) guidelines</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2024-10-18</date><deptcode>MEDS</deptcode><abstract>A growing and significant number of people with diabetes develop chronic kidney disease (CKD). Diabetes&#x2010;related CKD is a leading cause of end&#x2010;stage kidney disease (ESKD) and people with diabetes and CKD have high morbidity and mortality, predominantly related to cardiovascular disease (CVD). Despite advances in care over the recent decades, most people with CKD and type 2 diabetes are likely to die of CVD before developing ESKD. Hyperglycaemia and hypertension are modifiable risk factors to prevent onset and progression of CKD and related CVD. People with type 2 diabetes often have dyslipidaemia and CKD per se is an independent risk factor for CVD, therefore people with CKD and type 2 diabetes require intensive lipid lowering to reduce burden of CVD. Recent clinical trials of people with type 2 diabetes and CKD have demonstrated a reduction in composite kidney end point events (significant decline in kidney function, need for kidney replacement therapy and kidney death) with sodium&#x2010;glucose co&#x2010;transporter&#x2010;2 (SGLT&#x2010;2) inhibitors, non&#x2010;steroidal mineralocorticoid receptor antagonist finerenone and glucagon&#x2010;like peptide 1 receptor agonists. The Association of British Clinical Diabetologists (ABCD) and UK Kidney Association (UKKA) Diabetic Kidney Disease Clinical Speciality Group have previously undertaken a narrative review and critical appraisal of the available evidence to inform clinical practice guidelines for the management of hyperglycaemia, hyperlipidaemia and hypertension in adults with type 2 diabetes and CKD. This 2024 abbreviated updated guidance summarises the recommendations and the implications for clinical practice for healthcare professionals who treat people with diabetes and CKD in primary, community and secondary care settings.</abstract><type>Journal Article</type><journal>Diabetic Medicine</journal><volume/><journalNumber/><paginationStart/><paginationEnd/><publisher>Wiley</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>0742-3071</issnPrint><issnElectronic>1464-5491</issnElectronic><keywords>ACE inhibitor, hypertension, kidney disease, lifestyle, type 2 diabetes</keywords><publishedDay>17</publishedDay><publishedMonth>10</publishedMonth><publishedYear>2024</publishedYear><publishedDate>2024-10-17</publishedDate><doi>10.1111/dme.15450</doi><url/><notes>Invited Review</notes><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders/><projectreference/><lastEdited>2024-11-28T15:14:33.4235232</lastEdited><Created>2024-10-18T11:20:15.1598649</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>Indranil</firstname><surname>Dasgupta</surname><orcid>0000-0002-7448-2677</orcid><order>1</order></author><author><firstname>Sagen</firstname><surname>Zac&#x2010;Varghese</surname><order>2</order></author><author><firstname>Khuram</firstname><surname>Chaudhry</surname><order>3</order></author><author><firstname>Kieran</firstname><surname>McCafferty</surname><order>4</order></author><author><firstname>Peter</firstname><surname>Winocour</surname><orcid>0000-0002-1787-7496</orcid><order>5</order></author><author><firstname>Tahseen A.</firstname><surname>Chowdhury</surname><orcid>0000-0001-8878-2331</orcid><order>6</order></author><author><firstname>Srikanth</firstname><surname>Bellary</surname><order>7</order></author><author><firstname>Gabrielle</firstname><surname>Goldet</surname><order>8</order></author><author><firstname>Mona</firstname><surname>Wahba</surname><order>9</order></author><author><firstname>Parijat</firstname><surname>De</surname><order>10</order></author><author><firstname>Andrew H.</firstname><surname>Frankel</surname><order>11</order></author><author><firstname>Rosa M.</firstname><surname>Montero</surname><order>12</order></author><author><firstname>Eirini</firstname><surname>Lioudaki</surname><order>13</order></author><author><firstname>Debasish</firstname><surname>Banerjee</surname><orcid>0000-0002-6863-2325</orcid><order>14</order></author><author><firstname>Ritwika</firstname><surname>Mallik</surname><order>15</order></author><author><firstname>Adnan</firstname><surname>Sharif</surname><order>16</order></author><author><firstname>Naresh</firstname><surname>Kanumilli</surname><order>17</order></author><author><firstname>Nicola</firstname><surname>Milne</surname><order>18</order></author><author><firstname>Dipesh C.</firstname><surname>Patel</surname><order>19</order></author><author><firstname>Ketan</firstname><surname>Dhatariya</surname><orcid>0000-0003-3619-9579</orcid><order>20</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>21</order></author><author><firstname>Janaka</firstname><surname>Karalliedde</surname><orcid>0000-0002-2617-8320</orcid><order>22</order></author></authors><documents><document><filename>68024__32630__2d86eabeba4c4c1196cf5f0b7efa0bc5.pdf</filename><originalFilename>dme.15450.pdf</originalFilename><uploaded>2024-10-18T11:20:15.1414652</uploaded><type>Output</type><contentLength>631409</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; 2024 The Author(s). This is an open access article under the terms of the Creative Commons Attribution License (CC BY 4.0).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2024-11-28T15:14:33.4235232 v2 68024 2024-10-18 Current management of chronic kidney disease in type‐2 diabetes—A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney association ( ABCD ‐ UKKA ) guidelines 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2024-10-18 MEDS A growing and significant number of people with diabetes develop chronic kidney disease (CKD). Diabetes‐related CKD is a leading cause of end‐stage kidney disease (ESKD) and people with diabetes and CKD have high morbidity and mortality, predominantly related to cardiovascular disease (CVD). Despite advances in care over the recent decades, most people with CKD and type 2 diabetes are likely to die of CVD before developing ESKD. Hyperglycaemia and hypertension are modifiable risk factors to prevent onset and progression of CKD and related CVD. People with type 2 diabetes often have dyslipidaemia and CKD per se is an independent risk factor for CVD, therefore people with CKD and type 2 diabetes require intensive lipid lowering to reduce burden of CVD. Recent clinical trials of people with type 2 diabetes and CKD have demonstrated a reduction in composite kidney end point events (significant decline in kidney function, need for kidney replacement therapy and kidney death) with sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors, non‐steroidal mineralocorticoid receptor antagonist finerenone and glucagon‐like peptide 1 receptor agonists. The Association of British Clinical Diabetologists (ABCD) and UK Kidney Association (UKKA) Diabetic Kidney Disease Clinical Speciality Group have previously undertaken a narrative review and critical appraisal of the available evidence to inform clinical practice guidelines for the management of hyperglycaemia, hyperlipidaemia and hypertension in adults with type 2 diabetes and CKD. This 2024 abbreviated updated guidance summarises the recommendations and the implications for clinical practice for healthcare professionals who treat people with diabetes and CKD in primary, community and secondary care settings. Journal Article Diabetic Medicine Wiley 0742-3071 1464-5491 ACE inhibitor, hypertension, kidney disease, lifestyle, type 2 diabetes 17 10 2024 2024-10-17 10.1111/dme.15450 Invited Review COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Another institution paid the OA fee 2024-11-28T15:14:33.4235232 2024-10-18T11:20:15.1598649 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science Indranil Dasgupta 0000-0002-7448-2677 1 Sagen Zac‐Varghese 2 Khuram Chaudhry 3 Kieran McCafferty 4 Peter Winocour 0000-0002-1787-7496 5 Tahseen A. Chowdhury 0000-0001-8878-2331 6 Srikanth Bellary 7 Gabrielle Goldet 8 Mona Wahba 9 Parijat De 10 Andrew H. Frankel 11 Rosa M. Montero 12 Eirini Lioudaki 13 Debasish Banerjee 0000-0002-6863-2325 14 Ritwika Mallik 15 Adnan Sharif 16 Naresh Kanumilli 17 Nicola Milne 18 Dipesh C. Patel 19 Ketan Dhatariya 0000-0003-3619-9579 20 Steve Bain 0000-0001-8519-4964 21 Janaka Karalliedde 0000-0002-2617-8320 22 68024__32630__2d86eabeba4c4c1196cf5f0b7efa0bc5.pdf dme.15450.pdf 2024-10-18T11:20:15.1414652 Output 631409 application/pdf Version of Record true © 2024 The Author(s). This is an open access article under the terms of the Creative Commons Attribution License (CC BY 4.0). true eng http://creativecommons.org/licenses/by/4.0/
title Current management of chronic kidney disease in type‐2 diabetes—A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney association ( ABCD ‐ UKKA ) guidelines
spellingShingle Current management of chronic kidney disease in type‐2 diabetes—A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney association ( ABCD ‐ UKKA ) guidelines
Steve Bain
title_short Current management of chronic kidney disease in type‐2 diabetes—A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney association ( ABCD ‐ UKKA ) guidelines
title_full Current management of chronic kidney disease in type‐2 diabetes—A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney association ( ABCD ‐ UKKA ) guidelines
title_fullStr Current management of chronic kidney disease in type‐2 diabetes—A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney association ( ABCD ‐ UKKA ) guidelines
title_full_unstemmed Current management of chronic kidney disease in type‐2 diabetes—A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney association ( ABCD ‐ UKKA ) guidelines
title_sort Current management of chronic kidney disease in type‐2 diabetes—A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney association ( ABCD ‐ UKKA ) guidelines
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author Steve Bain
author2 Indranil Dasgupta
Sagen Zac‐Varghese
Khuram Chaudhry
Kieran McCafferty
Peter Winocour
Tahseen A. Chowdhury
Srikanth Bellary
Gabrielle Goldet
Mona Wahba
Parijat De
Andrew H. Frankel
Rosa M. Montero
Eirini Lioudaki
Debasish Banerjee
Ritwika Mallik
Adnan Sharif
Naresh Kanumilli
Nicola Milne
Dipesh C. Patel
Ketan Dhatariya
Steve Bain
Janaka Karalliedde
format Journal article
container_title Diabetic Medicine
publishDate 2024
institution Swansea University
issn 0742-3071
1464-5491
doi_str_mv 10.1111/dme.15450
publisher Wiley
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science
document_store_str 0
active_str 0
description A growing and significant number of people with diabetes develop chronic kidney disease (CKD). Diabetes‐related CKD is a leading cause of end‐stage kidney disease (ESKD) and people with diabetes and CKD have high morbidity and mortality, predominantly related to cardiovascular disease (CVD). Despite advances in care over the recent decades, most people with CKD and type 2 diabetes are likely to die of CVD before developing ESKD. Hyperglycaemia and hypertension are modifiable risk factors to prevent onset and progression of CKD and related CVD. People with type 2 diabetes often have dyslipidaemia and CKD per se is an independent risk factor for CVD, therefore people with CKD and type 2 diabetes require intensive lipid lowering to reduce burden of CVD. Recent clinical trials of people with type 2 diabetes and CKD have demonstrated a reduction in composite kidney end point events (significant decline in kidney function, need for kidney replacement therapy and kidney death) with sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors, non‐steroidal mineralocorticoid receptor antagonist finerenone and glucagon‐like peptide 1 receptor agonists. The Association of British Clinical Diabetologists (ABCD) and UK Kidney Association (UKKA) Diabetic Kidney Disease Clinical Speciality Group have previously undertaken a narrative review and critical appraisal of the available evidence to inform clinical practice guidelines for the management of hyperglycaemia, hyperlipidaemia and hypertension in adults with type 2 diabetes and CKD. This 2024 abbreviated updated guidance summarises the recommendations and the implications for clinical practice for healthcare professionals who treat people with diabetes and CKD in primary, community and secondary care settings.
published_date 2024-10-17T20:35:22Z
_version_ 1821348539120222208
score 11.04748

Similar Items